Retrophin takes on Questcor with ACTH analog, files for IPO

Retrophin shares are trading for about twice as much as they did at the beginning of 2013 in the Over the Counter market, so it makes sense for the company focused on therapies for rare and serious diseases to pursue an initial public offering that will move its stock to the Nasdaq index and raise $40m to fund assets recently added to Retrophin's development pipeline.